Back to top

Piper Sandler Sticks to Its Buy Rating for First Tracks Biotherapeutics Inc (TRAX)

In a report released today, Yasmeen Rahimi from Piper Sandler maintained a Buy rating on First Tracks Biotherapeutics Inc, with a price target of $...

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE: